# The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

> **NCT00034749** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 279 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00034749
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034749, "The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00034749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*